Trump Signs Order Allowing Psychedelic Drug Research

The executive order aims to accelerate clinical trials and expand access to psilocybin, MDMA, and other psychedelics.

Apr. 18, 2026 at 6:26pm

Got story updates? Submit your updates here. ›

A vibrant, neon outline of a human brain against a dark background, conceptually representing the potential of psychedelics to unlock new pathways in the mind.A visionary executive order could usher in a new era of psychedelic-assisted mental health treatment.Oklahoma City Today

Former President Donald Trump has signed an executive order that will allow for expanded research into psychedelic drugs like psilocybin and MDMA. The order directs federal agencies to accelerate clinical trials and explore ways to increase access to these substances for medical and therapeutic purposes.

Why it matters

Psychedelic drugs have shown promising results in treating conditions like depression, PTSD, and addiction, but have long been restricted due to their Schedule I classification. This order could pave the way for more widespread use of psychedelics in mental health treatment.

The details

The executive order calls on the Department of Health and Human Services, the Department of Veterans Affairs, and other agencies to identify and address barriers to psychedelic research and treatment. It also directs them to explore options for expanded access to these drugs, potentially including the creation of 'healing centers' where people could undergo psychedelic-assisted therapy.

  • The executive order was signed by former President Trump on April 15, 2026.

The players

Donald Trump

The former President of the United States who signed the executive order.

Got photos? Submit your photos here. ›

What they’re saying

“This is a historic moment that could revolutionize mental health treatment in this country.”

— Dr. Julie Holland, Psychiatrist and psychedelic researcher

What’s next

The executive order directs federal agencies to provide an initial report on their progress within 90 days.

The takeaway

This order represents a significant shift in the federal government's approach to psychedelics, potentially opening the door for more widespread therapeutic use of these substances to address mental health issues.